ValuEngine upgraded shares of Motif (NASDAQ:MTFB) from a sell rating to a hold rating in a report released on Wednesday morning.
MTFB has been the topic of several other research reports. Gabelli restated a hold rating on shares of Motif in a research report on Thursday, March 29th. Northland Securities began coverage on shares of Motif in a report on Monday, April 16th. They set an outperform rating on the stock. Finally, HC Wainwright reaffirmed a buy rating and set a $32.00 target price on shares of Motif in a report on Thursday, April 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of $19.50.
Get Motif alerts:
Motif stock opened at $9.50 on Wednesday. The company has a debt-to-equity ratio of -1.58, a quick ratio of 0.96 and a current ratio of 0.96. The firm has a market cap of $1,866.00, a PE ratio of -50.00 and a beta of 0.16. Motif has a fifty-two week low of $6.84 and a fifty-two week high of $13.75.
Motif Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.
To view ValuEngine’s full report, visit ValuEngine’s official website.